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To the Editor: Smoking has a major negative impact on global
health. The adverse effects of smoking continuation relative to
smoking cessation on coronary atherosclerosis are not well elucidated.
The aim of this study was in a cohort of long-term smokers to assesstery calcium (CAC) among participants with CAC ¼ 0 at b
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A total of 1,265 current or previous smokers 50 to 70 years old
with at least 20 pack-years and without coronary artery diseaseaseline (n ¼ 683) in ex-smokers (white), continued light (blue), and heavy smokers
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256(CAD) were recruited from the Danish Lung Cancer Screening
Trial, a randomized controlled trial initiated in 2004. All partici-
pants completed questionnaires on smoking annually as well as
undergoing multidetector computed tomography (MDCT) for
a period of 4 years. Only continuous smokers or ex-smokers without
CAD events during the study period were included. Continuous
smokers were categorized as light (1 to 17 cigarettes per day) and
heavy smokers (>17 cigarettes per day). Volumetric CAC scores
were measured at baseline and after 4 years. CAC development,
so-called incident CAC (CACi) and CAC progression (CACp)
were analyzed as proposed by McEvoy et al. (1). CACp was deﬁned
according to Hokanson et al. (2). Multivariable logistic regression
was used to determine associations between clinical variables and
CACi and CACp. Interaction analyses between clinical parameters
and CAC at baseline were included in the analysis of CACp to
account for potential change in effect dependent of CAC at base-
line. Statistical analyses were performed using SAS for Windows,
version 9.1 (SAS Institute, Cary, North Carolina).
Baseline characteristics included 45% women, with a median age
of 57 years and 34 pack-years. The frequency of CACi was higher in
continued smokers compared to ex-smokers and showed a dose-
response relationship with respect to extent of smoking (Fig. 1A).
Participants in whom CACi was observed (n ¼ 173) were older
(57 vs. 56 years of age, p ¼ 0.008) and were more likely to be male
(52% vs. 40%, p < 0.01) and to be treated with antihypertensive
agents (17% vs. 9%, p < 0.01), statins (8% vs. 3%, p < 0.01),
and/or antidiabetic agents (5% vs. 1%, p < 0.001). Similarly,
participants with CACi had more pack-years at study inclusion
(35 vs. 31 years, p< 0.001). Age, male gender, and continued heavy
smoking compared to ex-smoking were found to be independently
associated with an increased risk of CACi (Fig. 1C). There was no
interaction between pack-years and years of smoking cessation. The
frequency of CACp (n ¼ 481) was higher in continued smokers
compared to ex-smokers and showed a dose-response relationship
with respect to extent of smoking (Fig. 1B). Furthermore, partici-
pants with CACp were more likely to be older (59 vs. 57 years of
age, p < 0.0001) and male (66% vs. 48%, p < 0.0001), and have
hypertension (21% vs. 10%, p < 0.0001), hypercholesterolemia
(12% vs. 4%, p < 0.0001), or diabetes (4% vs. 1%, p < 0.001)
requiring treatment. Participants with CACp had higher baseline
CAC scores compared to participants without CACp (median
volumetric CAC 31 vs. 0, p < 0.0001). Furthermore, participants
with CACp had more pack-years (56 vs. 33 years, p < 0.0001).
Male gender, medical treatment of hypertension, and diabetes in
addition to continued heavy smoking when compared to ex-
smoking were found to be independently associated to CACp
(Fig. 1D). There were no interactions between smoking and clinical
parameters.
This is the ﬁrst longitudinal study to report the deleterious
effects of smoking continuation in long-term smokers with regard
to subclinical CAD.
One previous study found that age >40 years, smoking, and
diabetes were predictive of converting from CAC ¼ 0 to CAC
>0 during a 5-year period, which is in correlation with our results
(3). Earlier studies have sought to evaluate the effect of smoking
and smoking cessation on CAC cross-sectionally, although the
effect measured was in a population level rather than in an indi-
vidual level. A substudy of the Heinz Nixdorf Recall Study sought
to evaluate the effect of smoking in accumulation of CAC (4).
Based on ﬁndings they hypothesized that smoking cessation by the
age of 45, 55, and 65 years was associated with a CAC score at theage of 75 years that would have been reached 9, 6, and 3 years
earlier, respectively, had smoking been continued. Although, these
statistically modeled results are not directly comparable to our
study, the conclusion was concordant. In the CARDIA study (5),
risk factors for the prediction of CACi 15 years after baseline were
studied in a young cohort. Being a current smoker at baseline was
independently associated with CACi. However, the study could not
document an association between a 15-year change in smoking
habit and CACi. Our study population was older, smoking habits
were recorded in much greater detail and frequencies and quanti-
tative levels of CAC were by far higher than in the CARDIA
study, which might explain the discrepant results.
The following limitations should be taken into account. Our
study is only representative of current or former long-term smokers.
MDCT was performed without electrocardiography gating. How-
ever, previous comparisons of CAC obtained by gated versus
ungated MDCT have shown a high degree of concordance.
According to study design we did not measure cardiovascular
outcomes but rather the rate of CAC development and progression.
Furthermore, participants who developed manifest CAD during the
study period, possibly representing a group with higher rates of
CACp, were excluded.
In long-term smokers without known CAD continuation of
smoking is associated with more frequent development (odds ratio:
1.65; 95% conﬁdence interval: 1.05 to 2.65) and more aggressive
progression (odds ratio: 1.47; 95% conﬁdence interval: 1.06 to
2.04) of CAC. These ﬁndings support smoking cessation in long-
term smokers irrespective of the number of previous pack-years to
reduce the extent of CAC accumulation and thus potentially to
reduce the subsequent risk of CAD events.
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The Way to Determine
Coenzyme Q
Coenzyme Q (CoQ, ubiquinone) is a lipophilic molecule present
in all cells, located mainly in the inner mitochondrial membrane.
It is composed of a redox active benzoquinone ring conjugated to
an isoprenoid chain. The length of the chain differs among species;
in humans, it contains predominantly 10 isoprenoid units (CoQ10).
The synthesis of this chain shares the mevalonate pathway with
cholesterol and dolichol biosynthesis (1), in which 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG-Co A) reductase is a key
enzyme and target for statins. CoQ shuttles electrons from com-
plex I and complex II, to complex III of the mitochondrial respi-
ratory chain. It also functions as a lipid-soluble antioxidant, and is
involved in multiple aspects of cellular metabolism, including
pyrimidine nucleotide biosynthesis and beta-oxidation of fatty
acids (1).
Recently, Larsen et al. (2) studied the role of simvastatin on
skeletal muscle of patients with hypercholesterolemia. This
work indicates that simvastatin compromises glucose intolerance
and decreases insulin sensitivity, and also indicates a decrease of
coenzyme Q10 (CoQ10) in human skeletal muscle. However, these
results are based on an analytical mistake because the authors have
confused the lipid antioxidant CoQ10 with the encoded protein by
the COQ10B gene. COQ10B encodes for a mitochondrial protein
that does not participate in CoQ10 biosynthesis and apparently
contributes to CoQ10 function in respiration (3).
Their paper claims the changes of CoQ10 are caused by sim-
vastatin, but the authors have analyzed the expression of Coq10b
peptide using the antibody ab41997 (Abcam, Cambridge, United
Kingdom), included in their Figure 6, that should not be confusedwith the lipid CoQ10 content. The analysis of CoQ10 is carried
out in hexane-ethanol extracts by a high-performance liquid
chromatography system with a C18 reversed-phase column and
an electrochemical detector (4). This approach has previously
demonstrated that statin drug–related myopathy is associated with
a mild decrease in muscle CoQ10 concentration (5). The overall
work of Larsen et al. (2) is not invalidated by this comment, but the
results on CoQ10 levels should be revised.*Plácido Navas, PhD
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statin-related myopathy. Arch Neurol 2005;62:1709–12.ReplyWe appreciate the comment from Dr. Navas regarding our recent
report on simvastatin’s effect on skeletal muscle (1).
We agree with Dr. Navas that the coenzyme Q–binding protein
COQ10 homolog B (COQ10B) was measured. As Dr. Navas
writes in his letter, COQ10B is essential to the function of coen-
zyme Q10 (CoQ10) in regard to mitochondrial respiration (1). In
a paper by Barros et al. (2), it is suggested that COQ10B in yeast is
binding coenzyme Q6 (CoQ6), which is necessary for CoQ6 to
transport electrons in the electron transport chain, which subse-
quently leads to the transport of electrons and production of ATP
(2). CoQ6 is present in yeast and bacteria, and is equivalent to
CoQ10 in humans (3). Previously, it has been reported that statin
treatment decreases the amount of CoQ10 in skeletal muscle (4),
and in combination with the results from our present report
observing a reduced content of COQ10B (1), this indicates that
statin treatment has a similar effect on CoQ10 and COQ10B.
COQ10B is essential for electron transport in the mitochondrial
electron transport chain, and therefore, we believe that our conclusion
in the report is valid, as Dr. Navas also writes in his letter.*Steen Larsen, MSci
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